A new study to boost the number of expectant mothers having the Respiratory Syncytial Virus (RSV) immunisation and ...

Docquity, Southeast Asia's largest community of healthcare professionals (HCPs), and global biopharmaceutical leader AstraZeneca developed OAZisCare, an end-to-end patient support program (PSP) that ...

Under direction of Health Secretary Robert F. Kennedy Jr., the CDC is considering changes to its recommendations on vaccines ...

A panel of federal health experts recommended expanded vaccine options for several diseases, including RSV, meningitis, and chikungunya.

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

A new global study led by GlaxoSmithKline has found that a single dose of the RSV vaccine Arexvy (RSVPreF3 OA) offers strong ...